South Korea Vacuum Blood Collection Tube Market Size, Share, Growth, and Industry Analysis, By Product Type (Serum Tubes, Plasma Separation Tubes, Heparin Tubes, EDTA Tubes), By Material (Plastic, Glass) and Forecast, 2026-2034

South Korea Vacuum Blood Collection Tube Market Trends

Automation-Compatible Pre-Analytical Systems Gain Importance

Automated specimen processing is increasing the importance of standardized tube dimensions, reliable closures, barcode compatibility and consistent additive dosing. Large laboratories can process thousands of specimens daily, making even 1%–2% improvements in recollection or handling efficiency operationally relevant across annual volumes running into millions of specimens. Plastic tubes also reduce breakage exposure compared with conventional glass formats, while automated hematology and chemistry workflows increasingly favor standardized pre-analytical consumables.

Technology development is moving toward improved sample stability, microcollection and specialized analyte preservation. BD markets both evacuated Vacutainer systems and Microtainer products in South Korea, including tubes intended for hematology and chemistry applications. Globally, manufacturers are also scaling high-volume production: SEM Biotech reported a phase-one capacity target of 384 million tubes annually, illustrating the manufacturing scale increasingly available to diagnostic supply chains.

South Korea Vacuum Blood Collection Tube Market Drivers

Preventive Screening and High-Throughput Diagnostics Expand Tube Consumption

Routine chemistry, hematology, glucose, lipid and infectious-disease testing create recurring consumption because most tubes are single-use products. A comprehensive screening visit can involve multiple specimen containers, meaning 2–5 tubes per patient can translate into millions of units across large screening populations. Laboratory modernization, aging demographics and chronic-disease monitoring reinforce utilization, while automation can reduce manual handling stages by 10%–30% depending on laboratory configuration. Korea's established health-screening ecosystem further supports repeat blood testing across hospitals and dedicated screening centers.

South Korea Vacuum Blood Collection Tube Market Restraints

Pricing Pressure and Standardized Procurement Limit Supplier Margin Expansion

Vacuum tubes are high-volume consumables, exposing suppliers to procurement-driven price competition. A 3%–5% reduction in tender pricing can materially affect profitability when contracts involve hundreds of thousands or millions of tubes. Resin, rubber stopper, additive, sterilization, packaging and logistics costs can also move by 5%–15% during volatile procurement cycles. Hospitals simultaneously demand low defect and recollection rates, leaving suppliers limited room to offset input-cost increases through reduced quality expenditure.

South Korea Vacuum Blood Collection Tube Market Opportunities

Specialized Collection Systems Create Higher-Value Diagnostic Opportunities

Growth opportunities are emerging in molecular diagnostics, biomarker testing, liquid biopsy, therapeutic monitoring and analyte-stabilization applications. Specialized tubes can require preservation periods of 24–72 hours or longer, creating value beyond conventional chemistry collection. Global innovation demonstrates this direction: Streck launched Protein Plus BCT in 2024 for stabilization of plasma proteins, while microcollection technologies continue to broaden specimen collection options. Suppliers that combine specialized tubes with automation compatibility and traceability can address laboratories seeking both workflow efficiency and specimen integrity.

Challenges in South Korea Vacuum Blood Collection Tube Market

Quality Consistency Across High-Volume Production Remains Critical

Manufacturers must maintain vacuum accuracy, additive concentration, sterility and closure integrity across production runs that can exceed 100 million units annually. A defect level of only 0.1% represents 100,000 potentially affected tubes per 100 million units, emphasizing the importance of process control. Compliance with standards such as ISO 13485 and ISO 6710, alongside cleanroom manufacturing requirements, adds validation and quality-system costs.

South Korea Vacuum Blood Collection Tube Market Segmentation

The market is segmented by product type, material, application, end user and distribution channel. Product revenue is concentrated in plasma separation and serum tubes, which collectively represent approximately 56.1% of the 2026 product-based total. Material demand is led by plastic at approximately 63.6%, while glass contributes roughly 36.4%.

By Product Type

Plasma separation tubes constitute the largest product category at USD 7.97 million in 2026, rising from USD 7.72 million in 2025 to USD 10.32 million by 2034, at a 3.28% CAGR. Serum tubes closely follow at USD 7.94 million in 2026 and are projected to reach USD 10.22 million by 2034, recording a 3.21% CAGR.

EDTA tubes are the fastest-growing product category, with a 3.44% CAGR, increasing from USD 2.85 million in 2026 to USD 3.74 million by 2034. Heparin tubes grow at 3.10%, glucose tubes at 3.29%, ESR tubes at 3.08%, and other specialized tubes at 3.21%.

By Material

Plastic dominates material segmentation at USD 18.05 million in 2026, equivalent to approximately 63.6% of the material-based total. Revenue is forecast to reach USD 23.48 million by 2034, representing a 3.34% CAGR, supported by lower breakage risk, lighter weight and compatibility with high-throughput workflows.

Glass contributes USD 10.31 million in 2026, or approximately 36.4%, and is forecast to reach USD 13.19 million by 2034 at a 3.12% CAGR. Consequently, plastic is both the largest and fastest-growing material category.

By Application

Routine chemistry represents a core application because serum and plasma testing forms a substantial component of standard diagnostic panels. Plasma separation and serum tubes together generate USD 15.91 million in 2026, providing a quantitative indication of the large addressable specimen-collection requirement associated with chemistry-oriented workflows.

Blood sugar, coagulation, lipid-profile, infectious-disease and other testing applications provide diversified demand. Glucose tubes generate USD 2.27 million in 2026 and reach USD 2.94 million by 2034 at 3.29% CAGR, while specialized product requirements support continued differentiation across application workflows.

By End User

Hospitals and diagnostic laboratories constitute major institutional users because centralized laboratories process high volumes of chemistry, hematology and coagulation samples. The overall market advances from USD 28.35 million in 2026 toward USD 36.58 million in 2034, representing 3.23% CAGR, supporting continued procurement requirements across institutional settings.

Blood banks, ambulatory surgical centers, academic institutes and research laboratories create additional consumption. EDTA tubes' 3.44% CAGR and plasma separation tubes' USD 10.32 million 2034 value illustrate the continuing requirement for application-specific collection across these end-user environments.

By Distribution Channel

Direct tenders and distributors remain important channels for hospitals and high-volume diagnostic laboratories because institutional procurement typically emphasizes supply continuity, standardized specifications and bulk pricing. With USD 28.35 million in total 2026 demand, suppliers compete around reliability, regulatory compliance and portfolio breadth.

Retail and online channels complement institutional procurement for smaller laboratories and decentralized users. Market expansion to USD 36.58 million by 2034, representing approximately 29.0% growth over the 2026 level, creates incremental opportunities across both direct and intermediary distribution models.

South Korea Vacuum Blood Collection Tube Market Counties Outlook

The Seoul Capital Area—including Seoul, Incheon and Gyeonggi—represents the country's principal concentration of tertiary hospitals, diagnostic laboratories and specialized screening infrastructure. At the national level, demand totals USD 28.35 million in 2026, with plastic tubes accounting for approximately 63.6% and glass 36.4%. Seoul-area demand is particularly associated with hospital laboratories, preventive screening centers and high-throughput diagnostic facilities.

Busan, Daegu, Daejeon, Gwangju, Ulsan and provincial healthcare systems provide the remaining geographic demand base. National product consumption is led by plasma separation tubes at approximately 28.1% and serum tubes at approximately 28.0% in 2026, while EDTA represents around 10.1%. Expansion of regional laboratory networks and secondary hospitals supports consumption outside the Seoul Capital Area as national revenue approaches USD 36.58 million by 2034.

Top players in South Korean vacuum blood collection tube market

1. Becton, Dickinson and Company
2. Greiner Bio-One
3. Sekisui Medical
4. Terumo Corporation
5. SARSTEDT AG & Co. KG
6. Cardinal Health
7. Nipro Corporation
8. FL Medical
9. AdvaCare Pharma
10. Advin Health Care
11. Hindustan Syringes & Medical Devices
12. Streck
13. Improve Medical
14. CML Biotech
15. VACUETTE/Greiner AG

Published market sources identify BD, Greiner Bio-One, Terumo, Sekisui and other international manufacturers as notable participants in blood collection systems.

Top Two Companies

• Becton, Dickinson and Company:BD holds a strong competitive position through its Vacutainer portfolio and established South Korean commercial presence. The company offers serum-separation and microcollection solutions for chemistry and hematology workflows. Exact South Korea company-level percentage shares are not disclosed in the supplied dataset; therefore, no unsupported share estimate is assigned. Its positioning benefits from a broad product range, clinical familiarity and standardized pre-analytical systems in a national market valued atUSD 28.35 million in 2026and expanding at3.23% CAGR.
• Greiner Bio-One:Greiner Bio-One is positioned among established international suppliers of evacuated blood collection products and competes through broad tube configurations and laboratory-oriented collection systems. Industry sources consistently identify Greiner alongside BD, Terumo and other leading participants. Exact company percentage share for South Korea is not available from the supplied numerical dataset. Competitive opportunity is supported by plastic tubes'3.34% CAGRand the broader market's projected increase fromUSD 28.35 million in 2026toUSD 36.58 million by 2034.

Recent Developments in the South Korean Vacuum Blood Collection Tube Market

• 2025: SEM Biotech disclosed a phase-one manufacturing capacity target of 384 million vacuum blood collection tubes annually and a roadmap covering more than 100 products.
• 2025: SEM Biotech highlighted manufacturing aligned with ISO 13485:2016, ISO 6710:2017, and ISO Class 8 cleanroom requirements, reflecting continuing emphasis on standardized high-volume production.

Research Methodology

The assessment uses 2025 as the base year, 2026 as the current year and 2026–2034 as the forecast period, with 2022–2024 treated as historical years. Supplied market tables are the primary quantitative source for market value, product contribution, material contribution and CAGR calculations. The framework applies bottom-up segmentation and consistency checks across 7 product categories, 2 material categories, 6 applications, 5 end-user groups and 4 distribution channels. Secondary research is used only for industry context, company presence, technology developments and competitive validation. Minor differences between product-based and material-based totals reflect the supplied source tables and are retained rather than artificially reconciled.